Vertex Pharmaceuticals Inc (MIL:1VRTX)
€ 441.05 -2.05 (-0.46%) Market Cap: 112.08 Bil Enterprise Value: 107.49 Bil PE Ratio: 0 PB Ratio: 7.54 GF Score: 73/100

Q4 2018 Vertex Pharmaceuticals Inc Earnings Call Transcript

Feb 05, 2019 / 09:30PM GMT
Michael Partridge
Vertex Pharmaceuticals Incorporated - SVP of IR

Welcome to the Vertex Full Year and Fourth Quarter 2018 Financial Results Conference Call. This is Michael Partridge, Senior Vice President of Investor Relations for Vertex. Tonight, we will review our continued efforts to develop new medicines for all people with cystic fibrosis, recent advances in our research and development pipeline and our 2018 financial results and 2019 guidance.

Making prepared remarks on the call tonight, we have Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and I would like to welcome to the call, Paul Silva, Vertex's Interim Chief Financial Officer. Paul has been Vertex's Corporate Controller and Chief Accounting Officer since 2008. And he and his team have worked closely with the Investor Relations group since that time.

Following prepared remarks from Jeff, Stuart and Paul, Dr. Reshma Kewalramani, Chief Medical Officer, will join us for Q&A. We recommend that you access the webcast slides on our website as you listen to this call. The conference call is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot